Inactive Instrument

OvaScience Inc Share Price OTC Bulletin Board

US69014Q1013

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

11/23/11	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
30/22/30	Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc. Enter into First Amendment to Loan and Security Agreement	CI

Analysts' recommendations : OvaScience Inc

06/21/06	Millendo Therapeutics : Ladenburg Thalmann Downgrades Millendo Therapeutics to Neutral from Buy	MT
06/21/06	Millendo Therapeutics : SVB Leerink Downgrades Millendo Therapeutics to Market Perform From Outperform; Price Target is $2	MT
10/20/10	Millendo Therapeutics : Wedbush Adjusts Price Target for Millendo Therapeutics to $2 From $3, Maintains Neutral Rating	MT

More recommendations

Press Releases : OvaScience Inc

24/21/24	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
17/21/17	Tempest Therapeutics : BUSINESS (Form 8-K)	PU
17/21/17	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/21/12	Tempest Therapeutics : to Participate in William Blair 2021 Biotech Focus Conference	AQ
12/21/12	TEMPEST THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ

More press releases

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-0.71%	-6.35%	-2.99%	+9.59%	4.55TCr
REVOLUTION MEDICINES, INC.	+0.21%	-2.98%	+337.74%	+519.55%	4.37TCr
IQVIA HOLDINGS INC.	+1.74%	-2.24%	+39.82%	+20.76%	4.31TCr
BEONE MEDICINES AG	+1.38%	-3.28%	+6.84%	+67.62%	3.94TCr
CELLTRION, INC.	-1.44%	-5.26%	+8.97%	+39.76%	3.19TCr
ASCENDIS PHARMA A/S	+0.87%	-2.60%	-	-	1.73TCr
MEDPACE HOLDINGS, INC.	+0.75%	-0.64%	+19.75%	+110.17%	1.64TCr
EUROFINS SCIENTIFIC SE	-0.31%	-2.78%	+10.78%	+31.02%	1.42TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.93%	-3.55%	+82.00%	+41.17%	1.33TCr
Average	+0.49%	-3.57%	+62.86%	+104.96%	2.94TCr
Weighted average by Cap.	+0.41%	-3.67%	+74.58%	+124.28%

See all sector performances

Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.

Employees

Sector

Biotechnology & Medical Research

More about the company

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!

SEIZE THE OFFER!

11/23/11	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
30/22/30	Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc. Enter into First Amendment to Loan and Security Agreement	CI
30/21/30	Millendo Therapeutics, Inc. Joins Nicholas Maestas as Vice President, Strategy and Finance and It's Principal Financial Officer	CI
25/21/25	Millendo Therapeutics, Inc.(NasdaqCM:MLND) dropped from NASDAQ Composite Index	CI
25/21/25	Tempest Therapeutics Inc. completed the acquisition of Millendo Therapeutics, Inc. in a reverse merger transaction for approximately $180 million.	CI
23/21/23	Millendo Therapeutics : , Tempest Therapeutics Investors Approve Merger Proposals	MT
13/21/13	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
29/21/29	Millendo Therapeutics, Inc., Tempest Therapeutics Inc. - M&A Call
29/21/29	Millendo Therapeutics : Tempest, Millendo Agree to Merge, Combined Company to List on NASDAQ	MT
29/21/29	Millendo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	CI
29/21/29	Tempest Therapeutics Inc. entered into a definitive agreement and plan of merger to acquire Millendo Therapeutics, Inc. in a reverse merger transaction.	CI
28/21/28	Millendo Therapeutics, Inc. Announces Executive Changes	CI
28/21/28	Millendo Therapeutics, Inc. Plans to Reduce Its Workforce with Majority of Reduction in Personnel Expects to Complete by April 15, 2021	CI

OvaScience Inc Share Price OTC Bulletin Board

Stocks

US69014Q1013

Biotechnology & Medical Research

Latest news : OvaScience Inc

Analysts' recommendations : OvaScience Inc

Press Releases : OvaScience Inc

Other Biotechnology & Medical Research

Company Profile